Core Insights - Biomea Fusion (NASDAQ:BMEA) shares experienced a significant increase of 24% following the announcement of positive results from a mid-stage study of icovamenib for type 2 diabetes treatment over a 52-week period [2] Company Summary - The mid-stage study demonstrated that icovamenib provided lasting treatment effects for individuals with type 2 diabetes [2]